NCT07851012Not yet recruiting
Cardiotoxicity in Newly Diagnosed Acute Myeloid Leukemia Patients
Assessment of Cardiotoxicity in Newly Diagnosed Acute Myeloid Leukemia Patients: Anthracycline-Based Induction Versus Venetoclax - Hypomethylating Agent RegimensJ
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
The aim of this study is to evaluate and compare the cardiotoxic effects associated with anthracycline-based induction chemotherapy and those receiving a Venetoclax or HMA regimens after four cycles of chemotherpy in patients with newly diagnosed acute myeloid leukemia.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 146 (estimated)
- First submitted
- 15 Sept 2026
- Start date
- 14 Oct 2026
- Primary completion date
- 14 Oct 2027
- Lead sponsor
- Assiut University
- Diseases
- Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT07851012
What you commit to
- Study type: Observational
- Planned participants: 146
- From 14 Oct 2026 to the primary completion date, 14 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history of anthracycline or venetoclax\_HMAs exposure.
Other illness
- Persistent hemodynamically unstable arrhythmias.
Lab values
- Pre-existing severe structural heart disease (e.g., severe valvular heart disease, ischemic cardiomyopathy, basal LVEF \<50%).
Other
- Poor acoustic windows making reliable 2D-STE tracking impossible.
Who the study is looking for
- Age ≥16 years with newly diagnosed, histologically confirmed AML.Scheduled to receive either:- Cohort A (Intensive): Anthracycline-based induction - Cohort B (Non-Intensive): Venetoclax and / or Hypomethylating Agent based regimens
- Baseline LVEF ≥ 50% as measured by standard baseline echocardiography.
- Patient provided written, informed consent.
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.